Key facts
- This page summarizes Junyuan Jerry Wang's Form 4 filing for Nuvation Bio Inc. (NUVB).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 13 Nov 2024, 16:28.
Junyuan Jerry Wang - 11 Nov 2024 Form 4 Insider Report for Nuvation Bio Inc. (NUVB)
- Reporting relationship
- CEO, ANHEART THERAPEUTICS LTD., Director
- Issuer ticker
- NUVB
- Reported as of
- 11 Nov 2024
- Net transaction value
- -$162,883
- SEC form
- 4
- Accepted by SEC
- 13 Nov 2024, 16:28:31 UTC
- Prior SEC filing
- 05 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ron A. Metzger, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Junyuan Jerry Wang filed Form 4 for Nuvation Bio Inc. (NUVB) on 13 Nov 2024.
Change
- Previous filing in this sequence was filed on 05 Sep 2024.
- Current net transaction value: -$162,883.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NUVB
transaction
Class A Common Stock
Sale
- Transaction value
- $162,883
- Shares
- -56,361
- Change %
- -1.4%
- Price
- $2.89
- Shares after
- 3,866,228
- Date
- 11 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
NUVB
holding
Class A Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,246,458
- Date
- 11 Nov 2024
- Ownership
- By LLC
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance-based restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary transactions by the Reporting Person.
Footnote F2
Shares are held directly by WangWang, LLC, of which the Reporting Person is Manager.